NexusFi: Find Your Edge


Home Menu

 





GILD - Gilead Sciences, Inc.


Discussion in Stocks and ETFs

Updated
    1. trending_up 1,309 views
    2. thumb_up 3 thanks given
    3. group 1 followers
    1. forum 3 posts
    2. attach_file 0 attachments




 
Search this Thread

GILD - Gilead Sciences, Inc.

  #1 (permalink)
 
tturner86's Avatar
 tturner86 
Portland, Oregon
 
Experience: Intermediate
Platform: F-16CM-40
Trading: GBU-39
Posts: 6,191 since Sep 2013
Thanks Given: 10,459
Thanks Received: 12,695


Visit my NexusFi Trade Journal Started this thread Reply With Quote

Can you help answer these questions
from other members on NexusFi?
NexusFi Journal Challenge - April 2024
Feedback and Announcements
The space time continuum and the dynamics of a financial …
Emini and Emicro Index
ZombieSqueeze
Platforms and Indicators
Deepmoney LLM
Elite Quantitative GenAI/LLM
Are there any eval firms that allow you to sink to your …
Traders Hideout
 
Best Threads (Most Thanked)
in the last 7 days on NexusFi
Get funded firms 2023/2024 - Any recommendations or word …
61 thanks
Funded Trader platforms
38 thanks
NexusFi site changelog and issues/problem reporting
27 thanks
GFIs1 1 DAX trade per day journal
18 thanks
The Program
18 thanks
  #3 (permalink)
 
tturner86's Avatar
 tturner86 
Portland, Oregon
 
Experience: Intermediate
Platform: F-16CM-40
Trading: GBU-39
Posts: 6,191 since Sep 2013
Thanks Given: 10,459
Thanks Received: 12,695


Gilead Sciences Stock Is Falling On These Drug Setbacks GILD ABBV - Investors.com

Visit my NexusFi Trade Journal Started this thread Reply With Quote
Thanked by:
  #4 (permalink)
 
tturner86's Avatar
 tturner86 
Portland, Oregon
 
Experience: Intermediate
Platform: F-16CM-40
Trading: GBU-39
Posts: 6,191 since Sep 2013
Thanks Given: 10,459
Thanks Received: 12,695

Summary
  • The political flack over Gilead's HVC pricing continues.
  • Pricing concerns are overblown.
  • As a best in class market leader, Gilead will dominate and shares will eclipse $150 within 12 months.

The other day I was rifling through the comments on one of my previous articles on Gilead Sciences (NASDAQ:GILD), and a commenter requested an article about the politics surrounding Gilead's pricing of its Hep C drugs Sovaldi, and more recently, Harvoni. So, I began going through various articles, news reports and company statements focused on the uproar on pricing. I came to the conclusion that no article could discuss the politics of this issue without also addressing pricing and profits. I posit that these three "Ps" are the only thing holding back Gilead's price at this point. One only has to look at the company's fundamentals, exponential growth in sales and profits, and robust pipeline to understand that the company is grossly undervalued. I believe once pricing concerns subside and the market sees just how many patients Sovaldi/Harvoni are curing, the stock will take off.

Gilead Sciences: Pricing, Politics And Profits - Gilead Sciences, Inc. ([AUTOLINK]NASDAQ[/AUTOLINK]:GILD) | Seeking Alpha

Visit my NexusFi Trade Journal Started this thread Reply With Quote
Thanked by:




Last Updated on October 22, 2014


© 2024 NexusFi™, s.a., All Rights Reserved.
Av Ricardo J. Alfaro, Century Tower, Panama City, Panama, Ph: +507 833-9432 (Panama and Intl), +1 888-312-3001 (USA and Canada)
All information is for educational use only and is not investment advice. There is a substantial risk of loss in trading commodity futures, stocks, options and foreign exchange products. Past performance is not indicative of future results.
About Us - Contact Us - Site Rules, Acceptable Use, and Terms and Conditions - Privacy Policy - Downloads - Top
no new posts